Novartis telbivudine Phase III HBV data
This article was originally published in Pharmaceutical Approvals Monthly
novartis' hepatitis B agent telbivudine meets its primary endpoint of one-year response in the pivotal GLOBE trial, the firm reports July 28. The composite endpoint, "designed to assess if telbivudine was at least as effective as lamivudine [GlaxoSmithKline's Epivir], evaluated the combination of viral suppression…with either improved liver function…or loss of detectable hepatitis B e-antigen," Novartis says. The two-year, 1,350-patient trial is ongoing and includes both antigen positive and negative patients. "The one-year analysis of this trial will be the primary data used" in the NDA, which Novartis continues to project submitting by the end of 2005. Novartis believes that emerging Epivir resistance could be an advantage for telbivudine (1Pharmaceutical Approvals Monthly February 2005, p. 3)...
You may also be interested in...
Merck’s Januvia becomes the first DPP-4 inhibitor to reach the market. FDA clears Novartis’ nucleoside analog Tyzeka (telbivudine) for treatment of adults with chronic hepatitis B; the new molecular entity will be priced at a premium to GSK’s Epivir HBV (lamivudine). AstraZeneca’s Seroquel (quetiapine) gains an indication for treatment of depressive episodes associated with bipolar disorder. GlaxoSmithKline’s extended-release heart failure therapy Coreg CR (carvedilol) gains approval
Novartis plans three NME filings in 2005, including first oral VEGF agent, firm says during Jan. 20 R&D day. PTK787 has blockbuster potential in colorectal cancer, Novartis says. Nine more NME filings are scheduled for next two years
VMS businesses are deemed essential in Department of Homeland Security guidance that provides as basis for orders by most states and localities across the US. During an AHPA webinar, attorney Trent Norris says the federal government prefers leaving business exemptions to shut-down decisions to the states.